Jade Biosciences announces underwritten public offering of common stock

Jade Biosciences, Inc. (NASDAQ: JBIO) announced a proposed underwritten public offering of common stock shares or pre-funded warrants to purchase common stock shares. The clinical-stage biotechnology company said the offering is subject to market and other conditions.

The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of the securities offered at the public offering price, minus underwriting discounts and commissions. Jade stated there is no assurance regarding whether or when the offering may be completed or the actual size or terms.

Jade intends to use net proceeds from the offering, combined with existing cash, cash equivalents, and investments, to fund clinical trials, preclinical studies, and manufacturing for its programs. The funds will also support additional research and development activities, capital expenditures, working capital and general corporate purposes.

Jefferies, TD Cowen and UBS Investment Bank serve as joint book-running managers for the proposed offering. LifeSci Capital acts as a book-running manager while BTIG serves as lead manager.

The securities are being offered under a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission and declared effective on May 15, 2026. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC.

Jade Biosciences focuses on developing therapies for autoimmune diseases. The company's lead candidate, JADE101, targets the cytokine APRIL and is being evaluated for treating immunoglobulin A nephropathy. The pipeline includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an undisclosed antibody program.

You May Also Be Interested In

• NRx Pharmaceuticals prices public offering at $3.50 per share
• Aeva Technologies files mixed shelf offering registration
• BrightSpring stockholders plan 15 million share secondary offering